. Author manuscript; available in PMC: 2025 Jan 22.

Published in final edited form as: Clin Cancer Res. 2019 Oct 31;26(2):344–353. doi: 10.1158/1078-0432.CCR-19-0647

Table 2B.

Efficacy summary

IMWG Response	Arm A (n = 29)	Arm B (n = 16)
Complete response	1 (3.5)	0 (0.0)
Very good partial response	4 (13.8)	2 (12.5)
Partial response	11 (37.9)	2 (12.5)
Minimal response	5 (17.2)	4 (25.0)
Stable disease	6 (20.7)	7 (43.8)
Progression	2 (6.9)	1 (6.3)
Clinical benefit rate (MR or better)	21 (72.4)	8 (50.0)
Response rate (PR or better)	16 (55.2)	4 (25.0)

Evaluable patients, n = 45 (One patient in Arm A withdrew the consent before complete evaluation); Clinical response rate includes complete response, very good partial response, partial response, and minimal response; Response rate includes complete response, very good partial response, and partial response.